secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2026-08-06T11:52:23+00:00
Accession:  0001193125-26-336780
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q2 revenue $34.5M; $85M placement funds Phase 3 ROBBIN trial in MSS colon cancer
--------------------------------------------------------------------------------

- Q2 total revenue $34.5M (up from $25.7M YoY); pre-commercial product revenue $6.4M.
- Completed $85M private placement in July; warrants could add up to $255M.
- Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant MSS colon cancer to start Q1 2027; targets 38,000 US patients annually.
- Discontinued funding for BATTMAN Phase 3 study (CCTG sponsored) to prioritize ROBBIN.
- Near-term milestones: NEST/UNICORN manuscripts H2 2026; corporate webcast Sept 10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000119312526336780/0001193125-26-336780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000119312526336780/agen-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer